Mangoceuticals (MGRX) Common Equity (2022 - 2026)

Mangoceuticals has disclosed Common Equity across 5 years of filings, most recently posting $13.5 million for Q1 2026.

• Common Equity for Q1 2026 came in at $13.5 million, down 33.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.5 million (down 33.46% YoY), and the FY2025 annual result was $15.2 million, up 9.0% from the prior year.
• Common Equity came in at $13.5 million for Q1 2026 at Mangoceuticals, down from $15.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $20.3 million in Q1 2025 to a low of -$958468.0 in Q1 2024.
• The 5-year median for Common Equity is $13.7 million (2024), against an average of $9.6 million.
• Across the five-year window, Common Equity plunged 125.1% in 2024 and jumped 2212.82% in 2025, its largest moves.
• Mangoceuticals' Common Equity stood at $614029.0 in 2022, then rose by 26.18% to $774754.0 in 2023, then soared by 1699.93% to $13.9 million in 2024, then increased by 9.0% to $15.2 million in 2025, then decreased by 11.35% to $13.5 million in 2026.
• The last three Common Equity figures came in at $13.5 million (Q1 2026), $15.2 million (Q4 2025), and $15.7 million (Q3 2025), per Business Quant data.